SCHEMBL19683693

SCHEMBL19683693

CC(C)(C)c1cc(NC(=O)Nc2ccc(-n3nc(-c4ccc(OCCN5CCCCC5)cc4)c4c(N)ncnc43)cc2)no1

nearest known ligand 0.89

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 18/20 0.89
▸ CSF1R P07333 2/20 0.89
▸ RET P07949 2/20 0.89
▸ PDGFRB P09619 2/20 0.89
▸ KIT P10721 2/20 0.89
▸ DDR1 Q08345 2/20 0.89
▸ LCK P06239 1/20 0.89
▸ PDGFRA P16234 1/20 0.89
▸ CDK11B P21127 1/20 0.89
▸ CCNC P24863 1/20 0.89
▸ FLT4 P35916 1/20 0.89
▸ CDK8 P49336 1/20 0.89
▸ BTK Q06187 1/20 0.89
▸ DDR2 Q16832 1/20 0.89
▸ MKNK2 Q9HBH9 1/20 0.89
▸ KDR P35968 2/20 0.57
▸ ALK Q9UM73 2/20 0.57
▸ AURKA O14965 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20873198 0.95 FLT3 (0.89) FLT3CSF1RRETPDGFRBKIT
SCHEMBL19683612 0.94 RET (1.00) FLT3CSF1RRETPDGFRBKIT
SCHEMBL19683617 0.92 FLT3 (0.83) FLT3CSF1RRETPDGFRBKIT
SCHEMBL19683778 0.91 FLT3 (0.94) FLT3CSF1RRETPDGFRBKIT
SCHEMBL23219403 0.89 FLT3 (0.72) FLT3CSF1RRETPDGFRBKIT
SCHEMBL20873194 0.88 FLT3 (0.77) FLT3CSF1RRETPDGFRBKIT
SCHEMBL19683698 0.87 FLT3 (0.88) FLT3CSF1RRETPDGFRBKIT
SCHEMBL19683598 0.87 RET (0.87) FLT3CSF1RRETPDGFRBKIT
SCHEMBL19683594 0.87 FLT3 (0.87) FLT3CSF1RRETPDGFRBKIT
SCHEMBL20873204 0.86 FLT3 (0.75) FLT3CSF1RRETPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975082-B2 Inhibitor of FLT3 kinase and use thereof PRECEDO PHARMACEUTICALS CO., LTD (CN) 2021-04-13 — — US disclosed
EP-3466952-B1 1-(4-(4-AMINO-3-PHENYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)-PHENYL)-UREA DERIVATIVES AS FLT3 KINASE INHIBITORS FOR TREATING CANCER PRECEDO PHARMACEUTICALS CO LTD (CN) 2021-03-03 — — EP disclosed
EP-3466952-A1 NOVEL INHIBITOR FOR FLT3 KINASE AND USES THEREOF Precedo Pharmaceuticals Co., Ltd. (CN) 2019-04-10 — — EP disclosed
WO-2017206962-A1 NOVEL INHIBITOR FOR FLT3 KINASE AND USES THEREOF 合肥中科普瑞昇生物医药科技有限公司 2017-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975082-B2 Inhibitor of FLT3 kinase and use thereof FLT3, FLT1, FGFR1 FLT3 1/4885CSF1R 4/4885RET 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback